China has approved a new COVID-19 vaccine for emergency use, one that was developed by the head of its Center for Disease Control, adding to its arsenal.
Gao Fu, the head of China’s CDC, led the development of a protein subunit vaccine that was approved by regulators last week for emergency use, the Chinese Academy of Sciences’ Institute of Microbiology said in a statement Monday.
It is the fourth such vaccine to be given emergency use approval. China has approved four vaccines developed by three Chinese companies for general use.
The vaccine was developed jointly by Anhui Zhifei Longcom Biopharmaceutical Co. Ltd. and the Chinese Academy of Sciences. The team finished phase 1 and phase 2 clinical trials in October of last year and is currently conducting the last phase of trials in Uzbekistan, Pakistan and Indonesia, according to the statement.
The vaccine was approved for use in Uzbekistan on March 1.
The protein subunit vaccine is similar to many of the other vaccines that have been approved globally in that it trains the body to recognize the spike protein that covers the surface of the coronavirus vaccine, although the difference lies in how it tells the body to recognize the protein. Scientists grow a harmless version of the protein in cells and then purify it, before it is assembled into a vaccine and injected.
There is no publicly available information in peer-reviewed scientific journals about the clinical trial data showing efficacy or safety. A spokesperson for the company said that the data could not be shared at this time but that the company was actively providing the information to health authorities.
China has been slow in vaccinating its population of 1.4 billion people, despite having four vaccines approved for general use. The latest numbers, according to government officials at a press briefing Monday in Beijing, is that it has administered 64.98 million doses of vaccines.
China has targeted what it considers key populations for vaccination thus far, namely health care workers as well as those who work at the border or customs, and specific industries the government has selected. A second group, which has notably been absent thus far in comparison to many other countries, has been the elderly and those with pre-existing conditions.
The vaccines have previously been limited to adults 18-59 years old, as officials cited a lack of clinical trial data for those who are older, although the government appears to be signaling the limits are now being set aside. “We will promptly carry out mass vaccination of relevant populations,” Li Bin, a vice chair on the National Health Commission, said Monday.
China’s official Xinhua News Agency reported over the weekend that in certain neighborhoods in Beijing, local health centers started to offer the vaccines to those aged 60 and older.
China approves two more COVID-19 vaccines for wider use
© 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.
China approves a fourth COVID-19 vaccine for emergency use (2021, March 16)
retrieved 16 March 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022